Here, we report that cabergoline, a dopaminergic agonist, reduces the risk of breast cancer post-pregnancy in a <i>Brca1/P53</i>-deficient mouse model, with implications for human breast cancer prevention. The gene discussed is BRCA1; the disease is breast carcinoma.